Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors
- Details
- Category: Novo Nordisk
Novo Nordisk announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology. The objective of this 30 week trial was to assess the efficacy and safety of Ozempic® (semaglutide) 1.0 mg when added to SGLT-2 inhibitor (SGLT-2i) therapy.
Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China
- Details
- Category: Novartis
Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab). The data, part of a broader ongoing 52 week Phase III study in 543 patients, show 97.7% of patients treated with Cosentyx 300mg achieved PASI 75 and 80.9% achieved PASI 90 by week 12, with 87% of patients reaching PASI 90 by week 16.
Bayer Thrombosis Research Award 2019 goes to Dr. Changjun Yin
- Details
- Category: Bayer
The fourth winner of the Bayer Thrombosis Research Award has been chosen. The Scientific Committee of the Bayer Science & Education Foundation awarded the EUR 30,000 prize to Dr. Changjun Yin from the Institute for Cardiovascular Prevention at the Ludwig-Maximilians-University in Munich in recognition of his research on Atherosclerosis and Alzheimer's disease (AD) as inflammatory conditions with high risks to develop thrombosis-related diseases.
Jury upholds Amgen's patents on Repatha® (evolocumab)
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These patents describe and claim antibodies, like Amgen's innovative Repatha® (evolocumab) product, that bind to a specific region on PCSK9 and reduce LDL-C levels in the body.
Roche enters into definitive merger agreement to acquire Spark Therapeutics
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of US$ 114.50 per share in an all-cash transaction. This corresponds to a total transaction value of approximately US$ 4.3 billion on a fully diluted basis.
Brilinta’s Phase III THEMIS trial met primary endpoint in patients with established coronary artery disease and type-2 diabetes
- Details
- Category: AstraZeneca
The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of major adverse cardiovascular events (MACE) compared to aspirin alone.
Amgen, Cytokinetics and Servier announce start of METEORIC-HF, the second Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment.
More Pharma News ...
- Abbott and Novo Nordisk enter partnership to provide integrated digital solution to people with diabetes using insulin
- Ochsner Health System and Pfizer partner to develop innovative models for clinical trials
- Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease
- Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)
- Boehringer Ingelheim (Canada) Ltd. and IBM Canada announce first of its kind collaboration to integrate blockchain technology into clinical trials
- Merz delivers double-digit growth in strategic business areas
- The Union for International Cancer Control and Pfizer announce new phase of global grants initiative supporting metastatic breast cancer patients